MX337051B - Tratamiento de inflamacion cronica con un derivado de 1, 2, 4-triazolo [1,5a] piridina. - Google Patents

Tratamiento de inflamacion cronica con un derivado de 1, 2, 4-triazolo [1,5a] piridina.

Info

Publication number
MX337051B
MX337051B MX2013006118A MX2013006118A MX337051B MX 337051 B MX337051 B MX 337051B MX 2013006118 A MX2013006118 A MX 2013006118A MX 2013006118 A MX2013006118 A MX 2013006118A MX 337051 B MX337051 B MX 337051B
Authority
MX
Mexico
Prior art keywords
triazolo
treatment
chronic inflammation
pyridine derivative
compound
Prior art date
Application number
MX2013006118A
Other languages
English (en)
Other versions
MX2013006118A (es
Inventor
Pawel T Dobrzanski
Matthew M Seavey
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of MX2013006118A publication Critical patent/MX2013006118A/es
Publication of MX337051B publication Critical patent/MX337051B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta solicitud describe y proporciona un método para tratar enfermedades o desórdenes caracterizado por inflamación sistémica crónica, tal como artritis reumatoide, utilizando un compuesto que inhibe JAK2 quinasa.
MX2013006118A 2010-12-06 2011-12-05 Tratamiento de inflamacion cronica con un derivado de 1, 2, 4-triazolo [1,5a] piridina. MX337051B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42007810P 2010-12-06 2010-12-06
PCT/US2011/063272 WO2012078504A1 (en) 2010-12-06 2011-12-05 TREATMENT OF CHRONIC INFLAMMATION WITH A 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVE

Publications (2)

Publication Number Publication Date
MX2013006118A MX2013006118A (es) 2013-12-16
MX337051B true MX337051B (es) 2016-02-10

Family

ID=45346575

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006118A MX337051B (es) 2010-12-06 2011-12-05 Tratamiento de inflamacion cronica con un derivado de 1, 2, 4-triazolo [1,5a] piridina.

Country Status (6)

Country Link
US (1) US9034876B2 (es)
EP (1) EP2648725A1 (es)
JP (1) JP6046633B2 (es)
CA (1) CA2818936A1 (es)
MX (1) MX337051B (es)
WO (1) WO2012078504A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2818941A1 (en) * 2010-12-06 2012-06-14 Cephalon, Inc. Janus kinase 2 (jak2) inhibitor for the treatment of lupus
EP3079694A1 (en) * 2013-12-11 2016-10-19 Cephalon, Inc. Treatment of multiple sclerosis with a 1,2,4-triazolo [1,5a]pyridine derivative
CA3166545A1 (en) * 2020-01-29 2021-08-05 Igor THEURL Methods of using momelotinib to treat joint inflammation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20110063A1 (es) * 2008-06-20 2011-02-16 Genentech Inc DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
US20100029675A1 (en) * 2008-07-25 2010-02-04 Hwang Soo-In Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use
WO2010141796A2 (en) 2009-06-05 2010-12-09 Cephalon, Inc. PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES
CA2818941A1 (en) * 2010-12-06 2012-06-14 Cephalon, Inc. Janus kinase 2 (jak2) inhibitor for the treatment of lupus

Also Published As

Publication number Publication date
JP2013544291A (ja) 2013-12-12
WO2012078504A1 (en) 2012-06-14
MX2013006118A (es) 2013-12-16
US20130267535A1 (en) 2013-10-10
CA2818936A1 (en) 2012-06-14
EP2648725A1 (en) 2013-10-16
JP6046633B2 (ja) 2016-12-21
US9034876B2 (en) 2015-05-19

Similar Documents

Publication Publication Date Title
PH12018501065A1 (en) Compounds and compositions useful for treating disorders related to ntrk
IL227716A0 (en) Imidazo [1,5–f] [4,2,1] triazines for the treatment of neurological disorders
WO2013077921A3 (en) Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
WO2009011850A3 (en) Novel therapeutic compounds
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
WO2012114204A3 (en) Methods of treating mitochondrial dysfunction
WO2013056148A3 (en) Scd1 antagonists for treating cancer
WO2012125544A3 (en) Necroptosis inhibitors and methods of use therefor
MY165728A (en) Selective glycosidase inhibitors and uses thereof
WO2012007345A3 (en) Substituted imidazo[1,2-a]pyrimidines and -pyridines
MY175979A (en) Certain chemical entities, compositions and methods
TN2011000379A1 (en) [1, 2, 4] triazolo [1,5-a ] pyridines as kinase inhibitors
EP3380471B8 (en) Tetrahydro-8h-pyrido[1,2-a]pyrazine-8-ones as comt inhibitors for the treatment of neurodegenerative disorders
WO2012178015A3 (en) Lrrk2 inhibitors
WO2011091366A3 (en) Methods of treating or preventing periodontitis and diseases associated with periodontitis
AU2013218357A8 (en) Tetrahydro-quinazolinone derivatives as TANK and PARP inhibitors
WO2012125408A8 (en) Pegylated apelin and uses thereof
MX370253B (es) Composiciones de compuestos de jasmonato y métodos de uso de las mismas.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
TN2011000319A1 (en) Substituted quinazoline compounds
TN2012000610A1 (en) Heterocyclic compounds, their preparation and their therapeutic application
WO2012094328A3 (en) Hedgehog antagonists having zinc binding moieties
EP2839833A4 (en) TOPICAL PHARMACEUTICAL COMPOSITION, PROCESS FOR PREPARING TOPICAL PHARMACEUTICAL COMPOSITION, USE OF TOPICAL PHARMACEUTICAL COMPOSITION AND METHOD FOR TOPIC TREATMENT OF PSORIASIS, ATOPIAN DERMATITIS OR CHRONIC ECCEM
MX2013006118A (es) Tratamiento de inflamacion cronica con un derivado de 1, 2, 4-triazolo [1,5a] piridina.
PH12017500270A1 (en) Use of 1-phenyl-3-dimethylaminopropane compounds for treating rheumatoid pain

Legal Events

Date Code Title Description
FG Grant or registration